Second monotherapy in childhood absence epilepsy.

ABSTRACT:

Objective

To determine optimal second monotherapy for children with childhood absence epilepsy (CAE) experiencing initial treatment failure.

Methods

Children with CAE experiencing treatment failure during the double-blind phase of a randomized controlled trial comparing ethosuximide, valproic acid, and lamotrigine were randomized to open-label second monotherapy with one of the 2 other study therapies. Primary study outcome was freedom from failure proportion at week 16-20 and month 12 visits after randomization. Secondary study outcome was percentage of participants experiencing attentional dysfunction at these visits.

Results

A total of 208 children were enrolled, randomized, and received second therapy. At both week 16-20 visit and month 12 visit, ethosuximide's (6

SUBMITTER: Cnaan A 

PROVIDER: S-EPMC5224720 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature